GILD Stock UPDATES Gilead Sciences (GILD) 105.36 09/07/2014
Post# of 273323
Posted On: 09/07/2014 3:19:24 PM
Gilead Sciences (GILD) 105.36 $GILD
Is a Cheap Hepatitis C Cure About to Go Global?
Todd Campbell, The Motley Fool - Motley Fool - 16 mins ago
Source: Gilead Sciences Last December, the FDA ushered in a new era in hepatitis C treatment when it approved Gilead Sciences ' Sovaldi -- a nucleotide analog NS5B polymerase inhibitor that simply knocks-out hepatitis C cold. In trials, 90% of...
Meet 5 IBD 50 Stocks Expanding Into New Markets
at Investor's Business Daily - Sat Sep 06, 7:01AM CDT
The IBD 50 list ranks stocks on a combination of recent profit growth and key measures such as return on equity, sales growth and profit margins, listing the strongest stocks first. Today's IBD 50 includes five companies that are expanding into new...
'Fast Money' Recap: Stocks Climb, Bonds Fall This Week
at The Street - Sat Sep 06, 4:00AM CDT
The trading panel discussed the overall market and whether to trade Chinese stocks.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Why Gilead Sciences (GILD) Stock Is Down Today
at The Street - Fri Sep 05, 3:10PM CDT
Shares of Gilead Sciences (GILD) fell in morning trading on news it's close to a deal to bring cheaper versions of the hepatitis C drug Sovaldi to developing nations.
Most active Nasdaq-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Midday Glance: Biotechnology companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Why Gilead Is Falling On Drugs For Developing Nations
at Investor's Business Daily - Fri Sep 05, 2:15PM CDT
Shares of Gilead Sciences (GILD) are down amid news that the drugmaker is reportedly nearing a licensing deal to bring its blockbuster hepatitis C drug Sovaldi to developing countries such as India and Pakistan. Generic drugmakers would be able to...
Next Support Level for Gilead Sciences (GILD) is $103.98
Comtex SmarTrend(R) - Fri Sep 05, 12:25PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $107.71 today and has reached the first level of support at $105.42. Analysts will be watching for a cross of the next downside pivot targets of $103.98 and $100.25.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Stocks Sag In Light Trade; Taser Bolts Higher, Gilead Dips
at Investor's Business Daily - Fri Sep 05, 9:33AM CDT
Stocks slipped into thin losses at the start of trade Friday. The Dow Jones industrial average and the S&P 500 were down 0.1% apiece. The Nasdaq hung a fraction below its starting point. The stock market today opened to weak trade, down 4% on the...
Early Glance: Biotechnology companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
XOMA Corporation (XOMA) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:11AM CDT
XOMA Corporation (XOMA) was a big mover last session, as the company saw its shares rise over 6% on the day.
Nanosphere (NSPH) Slumps: NSPH Plunges 14.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Nanosphere, Inc. (NSPH) saw a big move last session,continuing the recent downtrend for NSPH, as the stock is now down 54.2% in the past one-month time frame.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Is a Cheap Hepatitis C Cure About to Go Global?
Todd Campbell, The Motley Fool - Motley Fool - 16 mins ago
Source: Gilead Sciences Last December, the FDA ushered in a new era in hepatitis C treatment when it approved Gilead Sciences ' Sovaldi -- a nucleotide analog NS5B polymerase inhibitor that simply knocks-out hepatitis C cold. In trials, 90% of...
Meet 5 IBD 50 Stocks Expanding Into New Markets
at Investor's Business Daily - Sat Sep 06, 7:01AM CDT
The IBD 50 list ranks stocks on a combination of recent profit growth and key measures such as return on equity, sales growth and profit margins, listing the strongest stocks first. Today's IBD 50 includes five companies that are expanding into new...
'Fast Money' Recap: Stocks Climb, Bonds Fall This Week
at The Street - Sat Sep 06, 4:00AM CDT
The trading panel discussed the overall market and whether to trade Chinese stocks.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Why Gilead Sciences (GILD) Stock Is Down Today
at The Street - Fri Sep 05, 3:10PM CDT
Shares of Gilead Sciences (GILD) fell in morning trading on news it's close to a deal to bring cheaper versions of the hepatitis C drug Sovaldi to developing nations.
Most active Nasdaq-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Midday Glance: Biotechnology companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Why Gilead Is Falling On Drugs For Developing Nations
at Investor's Business Daily - Fri Sep 05, 2:15PM CDT
Shares of Gilead Sciences (GILD) are down amid news that the drugmaker is reportedly nearing a licensing deal to bring its blockbuster hepatitis C drug Sovaldi to developing countries such as India and Pakistan. Generic drugmakers would be able to...
Next Support Level for Gilead Sciences (GILD) is $103.98
Comtex SmarTrend(R) - Fri Sep 05, 12:25PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $107.71 today and has reached the first level of support at $105.42. Analysts will be watching for a cross of the next downside pivot targets of $103.98 and $100.25.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Stocks Sag In Light Trade; Taser Bolts Higher, Gilead Dips
at Investor's Business Daily - Fri Sep 05, 9:33AM CDT
Stocks slipped into thin losses at the start of trade Friday. The Dow Jones industrial average and the S&P 500 were down 0.1% apiece. The Nasdaq hung a fraction below its starting point. The stock market today opened to weak trade, down 4% on the...
Early Glance: Biotechnology companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
XOMA Corporation (XOMA) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:11AM CDT
XOMA Corporation (XOMA) was a big mover last session, as the company saw its shares rise over 6% on the day.
Nanosphere (NSPH) Slumps: NSPH Plunges 14.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Nanosphere, Inc. (NSPH) saw a big move last session,continuing the recent downtrend for NSPH, as the stock is now down 54.2% in the past one-month time frame.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
(0)
(0)